Truist Securities analyst Jordan Levy maintains Array Technologies (NASDAQ:ARRY) with a Hold and raises the price target from $17 to $22.
Daré Bioscience Announces Publication In Menopause: The Journal of The North American Menopause Society Of Data from Phase 1/2 Open-Label Safety And Pharmacokinetics Study Of DARE-HRT1 In Healthy Postmenopausal Women
Daré Plans to Advance DARE-HRT1 into Single Phase 3 Efficacy Trial for Treatment of Vasomotor Symptoms (VMS) due to Menopause
DARE-HRT1 has the potential to be the first FDA-approved monthly intravaginal
